Bonnie Ramsey

Early Tuesday morning, Vertex Pharmaceuticals (NASDAQ: VRTX) issued a press release announcing that its two phase 3 studies of Lumacaftor in combination with ivacaftor met the primary endpoint with "statistically significant improvement in lung function." Shares of Vertex have...